News
PHVS
34.26
-0.61%
-0.21
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Immunocore Holdings (IMCR), Pharvaris (PHVS) and Moderna (MRNA)
TipRanks · 1d ago
Weekly Report: what happened at PHVS last week (1102-1106)?
Weekly Report · 1d ago
Weekly Report: what happened at PHVS last week (1026-1030)?
Weekly Report · 11/02 09:03
How Investors Are Reacting To Pharvaris (PHVS) Phase 3 Data Presentation
Simply Wall St · 10/30 14:34
This Monolithic Power Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday
Benzinga · 10/30 14:30
This Hilton Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Benzinga · 10/29 13:09
This Pentair Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Wednesday
Benzinga · 10/28 16:54
Analysts Are Bullish on Top Healthcare Stocks: Pharvaris (PHVS), AgomAb Therapeutics NV ADR (AGMB)
TipRanks · 10/26 13:20
This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Benzinga · 10/26 13:09
Weekly Report: what happened at PHVS last week (1019-1023)?
Weekly Report · 10/26 09:03
Is Pharvaris (PHVS) A Bargain After BofA Upgrade And Lower Clinical Risk?
Simply Wall St · 10/25 21:30
Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade
Benzinga · 10/23 18:06
Norwegian downgraded, Skydance upgraded: Wall Street’s top analyst calls
TipRanks · 10/23 14:01
Pharvaris rises after BofA upgrades to Buy
Seeking Alpha · 10/23 11:48
This Allegion Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Benzinga · 10/23 11:37
Pharvaris Price Target Maintained With a $44.00/Share by B of A Securities
Dow Jones · 10/23 10:48
Pharvaris Raised to Buy From Neutral by B of A Securities
Dow Jones · 10/23 10:48
B of A Securities Upgrades Pharvaris to Buy, Maintains Price Target to $44
Benzinga · 10/23 10:38
Pharvaris upgraded to Buy at BofA after ‘valuation reset’
TipRanks · 10/23 10:20
Pharvaris upgraded to Buy from Neutral at BofA
TipRanks · 10/23 10:15
More
Webull provides a variety of real-time PHVS stock news. You can receive the latest news about Pharvaris N.V. through multiple platforms. This information may help you make smarter investment decisions.
About PHVS
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.